Sangui Biotech International Stock Probability of Future Pink Sheet Price Finishing Over 0.0015

SGBI Stock  USD 0  0.00  0.00%   
Sangui Biotech's future price is the expected price of Sangui Biotech instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Sangui Biotech International performance during a given time horizon utilizing its historical volatility. Check out Sangui Biotech Backtesting, Sangui Biotech Valuation, Sangui Biotech Correlation, Sangui Biotech Hype Analysis, Sangui Biotech Volatility, Sangui Biotech History as well as Sangui Biotech Performance.
  
Please specify Sangui Biotech's target price for which you would like Sangui Biotech odds to be computed.

Sangui Biotech Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Sangui Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Sangui Biotech Inter can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Sangui Biotech Inter generated a negative expected return over the last 90 days
Sangui Biotech Inter has some characteristics of a very speculative penny stock
Sangui Biotech International currently holds 48.9 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Sangui Biotech Inter has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Sangui Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Sangui Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sangui Biotech Inter sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sangui to invest in growth at high rates of return. When we think about Sangui Biotech's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 69.19 K. Net Loss for the year was (63.34 K) with profit before overhead, payroll, taxes, and interest of 69.19 K.
Sangui Biotech International currently holds about 30.47 K in cash with (140.46 K) of positive cash flow from operations.
Roughly 13.0% of Sangui Biotech outstanding shares are owned by corporate insiders
Latest headline from investing.com: Amneal Pharmaceuticals exec sells shares worth 114,786

Sangui Biotech Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Sangui Pink Sheet often depends not only on the future outlook of the current and potential Sangui Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Sangui Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding204.2 M
Cash And Short Term Investments30.5 K

Sangui Biotech Technical Analysis

Sangui Biotech's future price can be derived by breaking down and analyzing its technical indicators over time. Sangui Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Sangui Biotech International. In general, you should focus on analyzing Sangui Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

Sangui Biotech Predictive Forecast Models

Sangui Biotech's time-series forecasting models is one of many Sangui Biotech's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Sangui Biotech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about Sangui Biotech Inter

Checking the ongoing alerts about Sangui Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Sangui Biotech Inter help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Sangui Biotech Inter generated a negative expected return over the last 90 days
Sangui Biotech Inter has some characteristics of a very speculative penny stock
Sangui Biotech International currently holds 48.9 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Sangui Biotech Inter has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Sangui Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Sangui Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sangui Biotech Inter sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sangui to invest in growth at high rates of return. When we think about Sangui Biotech's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 69.19 K. Net Loss for the year was (63.34 K) with profit before overhead, payroll, taxes, and interest of 69.19 K.
Sangui Biotech International currently holds about 30.47 K in cash with (140.46 K) of positive cash flow from operations.
Roughly 13.0% of Sangui Biotech outstanding shares are owned by corporate insiders
Latest headline from investing.com: Amneal Pharmaceuticals exec sells shares worth 114,786

Other Information on Investing in Sangui Pink Sheet

Sangui Biotech financial ratios help investors to determine whether Sangui Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sangui with respect to the benefits of owning Sangui Biotech security.